Alpharadin™ Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Algeta ASA
ClinicalTrials.gov Identifier:
NCT00748046
First received: September 5, 2008
Last updated: October 4, 2011
Last verified: October 2011
  Purpose

The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Alpharadin.


Condition Intervention Phase
Prostate Cancer
Metastases
Pharmacokinetics
Drug: Radium-223 chloride (Alpharadin™ )
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases

Resource links provided by NLM:


Further study details as provided by Algeta ASA:

Primary Outcome Measures:
  • All safety data, including adverse events, occurrence of treatment-emergent adverse events, changes in laboratory variables, vital signs, ECG, physical examination, long term radiation toxicity, including results of bone marrow biopsy [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Biodistribution, dosimetry and pharmacokinetics (whole body activity assessment, the counts in region-of-interest (ROIs) from anterior and posterior whole-body images, and the assay of activity in blood [ Time Frame: 6 days after injection ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Post-treatment PSA effect: PSA decline, time to PSA progression after PSA response [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Post-treatment bone markers effect: Changes in bone marker values from pre- to post administration [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Circulating tumor cells (CTCs) enumeration and role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: August 2008
Study Completion Date: October 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A
The patients will receive Alpharadin as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
Drug: Radium-223 chloride (Alpharadin™ )
Single dose, doses of 50 kBq/kg, 100 kBq/kg, or 200 kBq/kg body weight (0.0014, 0.0027 or 0.0054 mCi/kg)

Detailed Description:

Within the U.S., the trial is conducted under an IND sponsored by Bayer.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Must be ≥18 years of age.
  2. Have histologically or cytologically evidence of adenocarcinoma of the prostate.
  3. Have progressive castrate metastatic disease as shown by at least one of the following:

    Imaging modalities:

    Radionuclide Bone Scan: New osseous lesions. MRI or CT: At least a 20% increase in the sum of the LD of target lesions. or

    Biochemical progression:

    A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart.

  4. Have skeletal metastases confirmed by bone scintigraphy within the last 4 weeks. Evidence of at least 2 bone metastases on bone scan.
  5. Have castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels of testosterone must be continued.
  6. Patients who have failed initial hormonal therapy using either an orchiectomy or a GnRH agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks.
  7. Have Karnofsky performance status ≥60%.
  8. Have a life expectancy ≥6 months.
  9. Have the following laboratory requirements:

    • White Blood Count (WBC) ≥3,000/mm3
    • Absolute Neutrophil Count (ANC) ≥1,500/ mm3
    • Platelet (PLT) ≥100,000/ mm3
    • Hemoglobin (HGB) ≥10 mg/dl
    • Bilirubin ≤2.0 mg/dl (unless the patient has Gilbert's syndrome)
    • AST and ALT ≤2,5 times upper institutional limit of the normal range
    • Serum creatinine ≤2.0 mg/dl
  10. Must be able and willing to sign an informed consent indicating that he is aware of the investigational nature of this study in keeping with the policies of the institution and have provided written authorization for use and disclosure of protected health information.
  11. Must be willing and able to comply with the protocol, and agrees to return to the hospital for follow-up visits and examination.

Exclusion Criteria:

  1. Have received an investigational drug within 4 weeks prior to the administration of Alpharadin, or is scheduled to receive one during the treatment and post-treatment period.
  2. Have received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute adverse events as a result of such therapy.
  3. Have received prior hemibody external radiotherapy*.
  4. Have a need for immediate external radiotherapy.
  5. Have received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug.
  6. When receiving bisphosphonates, have changed the dose within 4 weeks before administration of study drug.
  7. Have started or stopped systemic steroids within a week prior to study drug administration, or are expected to be subject to changes in the systemic steroid medication
  8. Have imminent or established spinal cord compression based on clinical findings and/or MRI.
  9. Have other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not prostate cancer metastases
  10. Have small cell carcinoma.
  11. Have predominant visceral metastases (≥ 3 lung or liver lesions) or symptomatic lymph-adenopathy (scrotal or pedal edema).
  12. Any other serious illness or medical condition, for example:

    • any uncontrolled infection
    • any patient who has clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or any patient who has heart failure more severe than this (NYHA Heart Failure Class III or IV)
    • Crohn's disease or ulcerative colitis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00748046

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Algeta ASA
Bayer
Investigators
Principal Investigator: Michael J. Morris, MD Memorial Sloan-Kettering Cancer Center
  More Information

No publications provided

Responsible Party: Algeta ASA
ClinicalTrials.gov Identifier: NCT00748046     History of Changes
Other Study ID Numbers: BC1-08
Study First Received: September 5, 2008
Last Updated: October 4, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Algeta ASA:
Biodistribution
Radiation dosimetry
Pharmacokinetics
Safety

Additional relevant MeSH terms:
Neoplasm Metastasis
Prostatic Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on April 16, 2014